PEGLYTE POWDER 5.85 G
SODIUM CHLORIDE : 5.85 G SODIUM BICARBONATE : 6.76 G POTASSIUM CHLORIDE : 3.05 G MACROGOL : 238.18 G SODIUM SULFATE : 22.96 G · DIN 00777838 · PENDOPHARM DIVISION OF PHARMASCIENCE INC
Health Canada status: MARKETED
What is PEGLYTE POWDER?
PEGLYTE POWDER 5.85 G contains SODIUM CHLORIDE : 5.85 G SODIUM BICARBONATE : 6.76 G POTASSIUM CHLORIDE : 3.05 G MACROGOL : 238.18 G SODIUM SULFATE : 22.96 G. It is listed in the Health Canada Drug Product Database under DIN 00777838, held by PENDOPHARM DIVISION OF PHARMASCIENCE INC, supplied as POWDER FOR SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 22-May-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PEGLYTE POWDER used for?
PegLyte® Powder (PEG 3350 and Electrolytes) is indicated for: • bowel cleansing prior to colonoscopy or barium enema x-ray examination or surgical procedures requiring a clean colon. • the treatment of constipation
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00777838 |
|---|---|
| Brand name | PEGLYTE POWDER |
| Generic / active ingredient | SODIUM CHLORIDE : 5.85 G SODIUM BICARBONATE : 6.76 G POTASSIUM CHLORIDE : 3.05 G MACROGOL : 238.18 G SODIUM SULFATE : 22.96 G |
| Manufacturer | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
| Strength | 5.85 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | ORAL |
| Schedule | Ethical |
| ATC code | A06AD10 MINERAL SALTS IN COMBINATION |
| AHFS class | 56:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-May-2013 |
| Original market date | 1988-12-31 00:00:00 |
How is it stored and handled?
Store the sachets and bottle at room temperature, between 15°C and 30°C. Once reconstituted, the solution should be used within 48 hours after mixing if stored at room temperature. If kept refrigerated (2°C to 8°C), use within 30 days. Discard unused portion.
How is it supplied?
280 g bottle, Box of 4 x 70 g sachets
What can be used instead?
Other Canadian products sharing ATC code A06AD10 MINERAL SALTS IN COMBINATION. 1 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEO-TWO BOWEL EVACUANT SUPPOSITORIES | 627 MG | SUPPOSITORY | BEUTLICH L.P. | CANCELLED POST MARKET | DIN 02090074 |
| EAU PURGATIVE RIGA | 2.4 G / 30 ML | LIQUID | GLENDALE AGENCIES | CANCELLED POST MARKET | DIN 00421359 |
| ELECTROPEG SOLUTION | 6.7 G / 277 G | POWDER | TECHNILAB PHARMA INC. | CANCELLED POST MARKET | DIN 02230825 |
| GOLYTELY GI LAVAGE SOLUTION | 22.74 G / 4 L | POWDER FOR SOLUTION | BRAINTREE LABORATORIES INC. | CANCELLED POST MARKET | DIN 00652512 |
| KLEAN-PREP | 740 MG | POWDER FOR SOLUTION | RICHMOND PHARMACEUTICALS INC. | CANCELLED POST MARKET | DIN 00741175 |
| LYTEPREP | 2.97 G | POWDER | THERAPEX DIVISION DE E-Z-EM CANADA INC | CANCELLED POST MARKET | DIN 02239569 |
| LYTEPREP | 25 MMOL | POWDER FOR SOLUTION | THERAPEX DIVISION DE E-Z-EM CANADA INC | CANCELLED POST MARKET | DIN 00695335 |
| OCL SOLUTION | 1.68 MG | SOLUTION | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00709298 |
| PEGLYTE SOLUTION | 1.46 G | LIQUID | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00777846 |
| PMS-PEGLYTE | 3.05 G | POWDER FOR SOLUTION | PHARMASCIENCE INC | APPROVED | DIN 02471590 |
Who else supplies MINERAL SALTS IN COMBINATION worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MINERAL SALTS IN COMBINATION appears in 663 registered pack listings across 2 markets, published on 1 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.